[Influence of a new monophasic oral contraceptive on body metabolism].
Androgenic activity as adverse effects of oral contraception can influence on discontinuation of the therapy. New gestagens used in oral contraception do not reveal androgenic activity. The aim of the study is to assess the safety of the therapy with a new monophasic oral contraception on metabolism. 99 healthy women aged mean 23.5 +/- 2.1 years were enrolled in the study. They received a monophasic contraceptive pill containing 30 micrograms ethinylestradiol and 2.0 mg dienogest during 13 cycles. Biochemical parameters in blood were measured before and after 6 and 12 cycles of therapy. The concentrations of liver enzymes, glucose and lipids did not differ significantly. The study suggests that a new monophasic oral contraceptive pill containing 30 micrograms ethinylestradiol and 2.0 mg dienogest is safe and good tolerated preparation.